This study is to explore the driving genes and the molecular mechanism of malignant transformation of adenomyosis. This study acquired the formalin fixed paraffin-embedded (FFPE) tissue of patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA) treated at Peking Union Medical College Hospital from July 15, 2017 to July 15, 2019. The formalin fixed paraffin-embedded tissues from patients pathologically diagnosed with adenomyosis during this time period were also included as control specimens. The eutopic endometrium, normal adenomyosis tissue, and EC-AIA tissue were harvested from the FFPE tissue from patients with EC-AIA. The normal eutopic endometrium and normal adenomyosis tissue were obtained by laser microdissection. The driving genes and potential molecular mechanism of EC-AIA will be found by the technology of whole exome sequencing and transcriptomics (RNA-sequencing).

Inclusion Criteria:

• Pathological confirmed diagnosis with atypical hyperplasia and malignant transformation of adenomyosis glandular epithelium (including endometrioid, serous and clear cell carcinoma), with or without concurrent endometrial carcinoma
• Signed an approved informed consents

Exclusion Criteria:

• Not meeting all the inclusion criteria.
• The formalin fixed paraffin-embedded (FFPE) tissue was not acquired at the required time period.
• The patients enrolled had accompanied some other kinds of carcinoma (such as ovarian cancer, cervical cancer, primary peritoneal cancer).
• Patients had cancer history of certain organ (such as colorectal cancer, gastric cancer, etc.)

Study population includes two groups patients (about 22 cases in each group):

• Patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA)
• Patients pathologically diagnosed with adenomyosis